[Preoperative dilatation of the cervix uteri by vaginal application of 9-deoxo-16, 16-dimethyl-9-methylene PGE2 in pregnancy interruption during the 1st trimester. Double-blind clinical study].
Single vaginal application of a suppository containing 10 mg of 9-deoxo-16-PGE2 3 hours prior to suction curettage in nulliparous women with gestational ages from 8 to 12 weeks resulted in significant cervical softening (p less than 0.0001), and facilitated additional instrumental dilatation when required. Moderate side effects occurred in the majority of treated patients, disappeared however with appropriate medication. This procedure may thus be considered as effective, safe and reliable.
D015064:16,16-Dimethylprostaglandin E2 / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology*; D000028:Abortion, Induced / Q000379:methods*; D000328:Adult; D002584:Cervix Uteri / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004107:Dilatation and Curettage / Q000379:methods*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011300:Preoperative Care; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology*; D013488:Suppositories
D011459:Prostaglandins E, Synthetic; D013488:Suppositories; C025505:meteneprost; D015064:16,16-Dimethylprostaglandin E2
Dilatation pré-opératoire du col utérin par application vaginale de 9-deoxo-16, 16-diméthyl-9-méthylène PGE2 dans les interruptions de grossesse du 1er trimestre. Etude clinique en double aveugle.